Skip to main content

aTYR PHARMA INC

ATYR
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001339970

No open-market purchases or sales by aTYR PHARMA INC insiders were filed in the last 90 days; 89 institutions reported holding it in 13F filings for Q2 2026, worth $23.2M in total; no superinvestor holds it.

Q3 2021 vs. Q2 2021

How the institutions holding aTYR PHARMA INC changed between Q2 2021 and Q3 2021.

All holders in Q3 2021All holders in Q2 2021

13F holders of ATYR: Q2 2021 compared with Q3 2021
MeasureQ2 2021Q3 2021Change
Holders2942+13
Shares6.92M19.0M+12.0M (+174.0%)
Value$33.8M$172.1M+$138.4M (+409.9%)

New holders (17)

Institutions that held aTYR PHARMA INC at the end of Q3 2021 but not at the end of Q2 2021.

Institutions new to ATYR in Q3 2021
InstitutionSharesValue% of portfolio
VR Adviser, LLC1,565,000$14.2M1.83%
Tang Capital Management LLC1,113,453$10.1M2.10%
Baker Bros. Advisors LP625,000$5.67M0.02%
Stonepine Capital Management, LLC410,535$3.73M1.70%
EAM Investors, LLC259,791$2.36M0.40%
EAM Global Investors LLC152,792$1.39M0.33%
Virtu Financial LLC143,677$1.30M0.11%
Jane Street Group, LLC136,901$1.24M0.00%
Cubist Systematic Strategies, LLC51,327$466.0K0.01%
Marshall Wace, LLP43,006$390.0K0.00%
Cutler Group LP15,524$140.0K0.01%
Tocqueville Asset Management L.P.14,850$135.0K0.00%
Price T Rowe Associates Inc12,024$109.0K0.00%
Sheaff Brock Investment Advisors, LLC11,000$100.0K0.01%
Carmichael Hill & Associates, Inc.300$3.00K0.00%
Charter Oak Capital Management, LLC150$1.00K0.00%
Advisor Group Holdings, Inc.1$00.00%

Sold out (4)

Institutions that held aTYR PHARMA INC at the end of Q2 2021 and filed for Q3 2021 without it.

Institutions that sold out of ATYR in Q3 2021
InstitutionShares, Q2 2021Value, Q2 2021
Acadian Asset Management LLC42,724$208.0K
XTX Topco Ltd12,265$60.0K
UBS Group AG3,164$15.0K
Royal Bank of Canada1$0